Bologna, Italy

Elena Dichiarante

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Eleison Pharmaceuticals, LLC, Targent, LLC. Active years: 2020-2022.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Elena Dichiarante

Introduction

Elena Dichiarante is a prominent inventor based in Bologna, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor agents. Her work has led to the creation of innovative crystalline polymorphs that have potential applications in cancer treatment.

Latest Patents

Elena Dichiarante holds 2 patents. Her latest patents focus on crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol, a known antitumor agent. These patents describe various polymorphic forms of dibromo dulcitol (DBD) and outline methods for producing these new crystalline forms. Additionally, the patents detail methods for utilizing these polymorphic forms in cancer treatment.

Career Highlights

Throughout her career, Dichiarante has worked with notable companies in the pharmaceutical industry. She has been associated with Targent, LLC and Eleison Pharmaceuticals, LLC, where she has contributed her expertise in drug development and innovation.

Collaborations

Elena has collaborated with various professionals in her field, including her coworker Stefano Luca Giaffreda. Their joint efforts have further advanced the research and development of effective cancer treatments.

Conclusion

Elena Dichiarante's innovative work in the field of pharmaceuticals highlights her commitment to advancing cancer treatment through her patented inventions. Her contributions continue to impact the industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…